Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

Viking Therapeutics (NASDAQ: VKTX) has intrigued investors over the past year and a half because it's involved in a potential ...

Key art for 'Deadliest Catch: The Viking Returns' featuring Captain Sig Hansen. Image via Discovery Channel Since 2005, Deadliest Catch has amazed fans with its exciting action and heart-stopping ...

A second analyst voices positive thoughts on Viking's new GLP-1 weight loss drug. Phase 3 clinical trial data on VK2735 arrives later this year, and phase 2 data on a GLP-1 pill could come out as ...

Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...

It has been a little more than two months since my last Viking Therapeutics, Inc. (NASDAQ:VKTX) article, where I highlighted their promising pipeline for obesity, NASH/MASH, and X-ALD programs that ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...